Prenetics Global Limited, a dual-headquartered healthcare company in Hong Kong and the U.S., announced Wednesday its aggressive entry into cryptocurrency by purchasing 【$20 million worth of Bitcoin】 at an average price of $106,712 per BTC. The initial acquisition of 187 BTC represents just the beginning of what the company describes as a long-term strategy to become a major corporate holder of the digital asset.
The healthcare firm simultaneously revealed two strategic appointments to bolster its crypto initiatives. Andy Cheung, former COO of OKEx, joins the board while Tracy Hoyos Lopez—Kraken's strategic initiatives chief and the architect behind former President Trump's pro-crypto campaign shift—joins an elite advisory team. ——This marks the first healthcare company to combine political crypto expertise with substantial Bitcoin investments——
Following the announcement, Prenetics' Nasdaq-listed shares (PRE) surged 8.7%, reflecting investor confidence in the unconventional strategy. The company currently holds 【$117 million in liquid assets】 including its new Bitcoin position, short-term investments, and cash reserves.
The move comes months after the Trump administration's March executive order establishing a "Strategic Bitcoin Reserve," which saw multiple U.S. corporations adopting similar treasury strategies. Interestingly, the U.S. government currently holds approximately 200,000 BTC seized from various legal cases—a stockpile some advisors suggest expanding through innovative methods like revaluing gold certificates.
Prenetics' decision challenges traditional healthcare sector investment patterns, coinciding with a Swedish health firm's recent 45% stock jump after announcing Bitcoin purchases. Market analysts note growing interest in "budget-neutral" crypto acquisition strategies that avoid taxpayer funds while gaining exposure to digital assets.
As of press time, Bitcoin maintains volatility around the $107,000 level, with industry watchers monitoring whether other healthcare companies will follow Prenetics' unconventional approach to corporate finance.